U.S. Deep Brain Stimulation In Parkinson’s Disease Market To Reach $849.50 Million By 2030

U.S. Deep Brain Stimulation In Parkinson’s Disease Market Growth & Trends

The U.S. deep brain stimulation in parkinson’s disease market size is anticipated to reach USD 849.50 million by 2030, registering a CAGR of 7.29% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is driven by various factors, such as novel product launches, and rising healthcare expenditure. Increasing regulatory approvals play a crucial role in driving market growth as they provide a level of assurance to healthcare professionals and patients regarding the safety and efficacy of these devices, thereby encouraging their adoption in clinical practice. For instance, in January 2024, FDA clearance for Abbott's Liberta RC DBS Device represented a significant milestone in advancing therapeutic interventions for PD.

Liberta RC DBS, distinguished as the smallest rechargeable DBS device in its class, introduced notable technological features, such as the NeuroSphere Virtual Clinical, enabling remote programming capabilities. This regulatory endorsement underscored adherence of the device to stringent safety and efficacy standards and positioned it as a pioneering solution in the field of neuromodulation. The incorporation of remote programming capabilities in the Liberta RC DBS device by Abbott aligns strategically with prevailing healthcare trends, augmenting patient convenience and broadening the device's acceptance within the medical community.

Abbott's recent achievement of securing FDA clearance for Liberta RC DBS is anticipated to catalyze transformative shifts in market dynamics, propelling heightened interest and fostering increased adoption within the U.S. DBS sector for PD treatment.

 Request a free sample copy or view report summary: U.S. Deep Brain Stimulation In Parkinson’s Disease Market Report

U.S. Deep Brain Stimulation In Parkinson’s Disease Market Report Highlights

• The dual-channel segment is expected to register the fastest CAGR of 7.87% from 2024 to 2030

• This growth is attributed to technological advancements and novel product launches by industry key players

• One of the key factors driving the market growth is increasing regulatory approval for deep brain stimulation (DBS) devices in Parkinson’s disease (PD) treatment

• Regulatory approvals offer opportunities for manufacturers to market and commercialize their devices, fostering competition

• This competition often results in technological advancements, device design improvements, and potentially more cost-effective options, which further contribute to market growth

U.S. Deep Brain Stimulation In Parkinson’s Disease Market Segmentation

Grand View Research has segmented the U.S. deep brain stimulation in Parkinson’s disease market on the basis of product:

U.S. Deep Brain Stimulation In Parkinson’s Disease Product Outlook (Revenue, USD Million, 2018 - 2030)

• Single-channel

• Dual-channel

List of Key Players in U.S. Deep Brain Stimulation In Parkinson’s Disease Market

• ABBOTT

• Medtronic

• Boston Scientific Corporation